NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Climb Bio, Inc. (CLYM) Stock Analysis

Climb Bio, Inc. (CLYM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CLYM

$15.52

+$0.93 (+6.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLYM with… →

CLYM Key Statistics

As of Sep 4, 2026
Trading
Open
$14.49
Previous Close
$14.59
Day's Range
14.28–15.96
52-Week Range
1.54–18.33
Volume
1.50M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.10
Valuation
Market Cap
$891.41M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.87
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$59.85M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.44M
1-Year Return
+566.09%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
1.44M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CLYM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+288.00%
2025+122.22%
2024−33.33%
2023−26.43%
2022−64.91%
2021 (partial year)−34.21%

As of September 4, 2026.

CLYM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$59.85M—
2024$0.00−$73.90M—
2023$0.00−$35.12M—
2022$0.00−$45.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$67.88M−$59.85M—
2024$0.00—−$30.36M−$73.90M—
2023$0.00—−$40.28M−$35.12M—
2022$0.00—−$45.14M−$45.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLYM Valuation vs Biotechnology Median

Median of 656 stocks
MetricCLYMBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Climb Bio, Inc. (CLYM) is capitalised at $891.41M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 28 employees.

CLYM last closed at $15.52 on September 4, 2026. That is +$0.93 (+6.37%) against the previous close. Over the past 52 weeks the price has ranged from $1.54 to $18.33. The latest close sits 907.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $59.85M. Profit margin runs at 0%. Trailing earnings per share are −0.87.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +566.09%. Across 5 years the annualized return works out at −10.85%. Beta against the wider market is reported at 0.1. Annualized volatility over the trailing 5 years is 105.84%.

Growth & Income

The record shows no dividend for CLYM.

So far in 2026 the price is +288.00%. The strongest complete calendar year on file is 2025 at +122.22%; the weakest is 2022 at −64.91%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Climb Bio, Inc. (CLYM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Climb Bio, Inc. CLYM $891.41M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Climb Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Climb Bio, Inc.

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Visit website →